Charter Research - Winter Park

Orlando, Florida 32803

2 studies enrolling now · 15 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Brain Diseases, Cardiovascular Diseases, Central Nervous System Diseases, Dementia, Mental Disorders, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Nervous System Diseases, Neurocognitive Disorders, Neurodegenerative Diseases

Studies at this site

• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight — Recruiting now
• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight — Recruiting now
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease — Completed
• A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes — Running, not enrolling
• A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight — Completed
• A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Completed
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Running, not enrolling
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
• A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight — Completed
• A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight — Completed
• A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity — Running, not enrolling
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Running, not enrolling
• A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes — Withdrawn before enrolling
• A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes — Stopped early